This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Scholar Rock (NASDAQ: SRRK; the "Company"), today announced that the company granted inducement equity awards covering an ...

Scholar Rock Holding (SRRK) is back in focus after updating investors on an FDA warning letter sent to its manufacturing partner, Catalent Indiana, along with plans to resubmit its biologics license ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes ...

Histological sample of skeletal muscle tissue under a microscope. Veru is testing a muscle-building drug in combination with Novo Nordisk's Wegovy to improve body composition in people with obesity ...

Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 “These ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...